Latest Insulin Stories
Enter today for a chance to win a trip to the 2013 IndyCar® Series finale BIRMINGHAM, Ala., April 5, 2013 /PRNewswire/ -- Novo Nordisk, a world leader in diabetes care, and IZOD IndyCar Series driver Charlie Kimball today kicked off a new contest asking people to support Charlie by encouraging their friends and family to join the Race with Insulin(®) crew. Now through September 15, by sharing Kimball's story about the importance of team support with two or more friends or family,...
OSSINING, N.Y., April 5, 2013 /PRNewswire/ -- Given the popularity of the BBC Video "Eat Fast Live Longer" by Dr. Michael Mosley, lots of people are trying intermittent fasting. We like Dr. Michael Mosley who does an excellent job as host. Some swear by intermittent fasting, saying it's a way to lose weight that they can tolerate. Others say it's just as health-enhancing as calorie restriction. LivingTheCR Way.com (http://www.livingthecrway.com/landing.aspx?ReturnUrl=%2fhome.aspx)...
INVOKANA(TM) is the first in a new class of type 2 diabetes medications available in the United States RARITAN, N.J., March 29, 2013 /PRNewswire/ -- Janssen Pharmaceuticals, Inc. announced today the U.S. Food and Drug Administration (FDA) has approved INVOKANA(TM) (canagliflozin) for the treatment of adults with type 2 diabetes. INVOKANA(TM) is the first in a new class of medications called sodium glucose co-transporter 2 (SGLT2) inhibitors to be approved in the United States. It...
DUBLIN, March 27, 2013 /PRNewswire/ -- Research and Markets announces the addition of "China Insulin Industry Report, 2012-2015 [http://www.researchandmarkets.com/research/b6c5bv/china_insulin ]" to its catalogue. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Due to high technological content and entry barriers, Chinese insulin market is monopolized by foreign corporations. In 2011, the combined market share of the three world-renowned...
Marketing application for the sodium glucose co-transporter-2 inhibitor follows submission of New Drug Application to U.S. Food and Drug Administration RIDGEFIELD, Conn. and INDIANAPOLIS, March 26, 2013 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced the European Medicines Agency (EMA) has accepted for review a marketing authorization application (MAA) for the investigational sodium glucose co-transporter-2 (SGLT2) inhibitor empagliflozin*,...
Company Takes Important Step Toward Sucanon®'s Entry Into the US Market LAS VEGAS, Nev., March 26, 2013 /PRNewswire/ -- PharmaRoth Labs, Inc. (OTCPink: FROI) the exclusive producer, marketer & distributor of Sucanon®, an oral Type-II Diabetes treatment, proudly announced that the United States Food and Drug Administration (FDA) has received the Company's completed New Dietary Ingredient (NDI) Notification. The primary purpose of the NDI Notification process is to determine the...
LAS VEGAS, March 25, 2013 /PRNewswire/ -- PharmaRoth Labs, Inc. (OTCPink: FROI) the exclusive producer, marketer & distributor of Sucanon®, an oral Type-II Diabetes treatment, announced today that the name of the company has been changed from Fero Industries, Inc. to PharmaRoth Labs, Inc. The company also relocated corporate headquarters to Las Vegas, Nevada from Canada. Luis Lopez, CEO of PharmaRoth Labs states: "We changed the name to PharmaRoth Labs to better reflect our...
Marketing application for the sodium glucose co-transporter-2 inhibitor follows completion of Phase III registration trials RIDGEFIELD, Conn. and INDIANAPOLIS, March 25, 2013 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced that a New Drug Application (NDA) for the investigational sodium glucose co-transporter-2 (SGLT2) inhibitor empagliflozin* was recently submitted to the Food and Drug Administration (FDA) in the United States for the...
Organization to share resources from partnership with Lilly Diabetes that stress importance of advance planning for people with diabetes NEW ORLEANS, March 25, 2013 /PRNewswire/ -- News Highlights: @TheAACE attends Hurricane Conference to share planning tips for people w/ #diabetes; prgm w/Lilly Diabetes offering emergency tips since '06 @TheAACE, in partnership with Lilly Diabetes, offers emergency planning tips for people with #diabetes at www.empoweryourhealth.org Lilly...
JERUSALEM, March 21, 2013 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that its abstract, titled "Dose response to oral insulin capsules in fasting, healthy subjects," has been selected for a poster presentation at the 73rd Scientific Sessions of the American Diabetes Association, being held on June 21-25, 2013, in Chicago, IL, USA. In addition, the work was selected to be...
Latest Insulin Reference Libraries
The pancreas is a digestive and an endocrine organ with both endocrine and exocrine functions. It is about six inches long located in the upper portion of the abdominal cavity. The head of the pancreas lies within the indentation of the duodenum and is connected to it by the pancreatic duct. The uncinate process extends from the head and the neck connects to the body of the pancreas, which lies directly behind the stomach. The tail of the pancreas extends to the left side of the body and is...
Insulin, a hormone, is used to regulate carbohydrate and fat metabolism in the body. Insulin causes cells to take up glucose from the blood and store it as glycogen in the liver and muscle. This hormone stops the body from using fat as an energy source by inhibiting the release of glucagons. Without insulin the body fails to take glucose into the bodies cells and in turns uses fat as an energy source. It also has several other anabolic effects throughout the body. Diabetes mellitus results...
